SYGNIS presents your innovative True Prime (TM) technology on the Single Cell Genomics Conference 2015
DGAP-News: SYGNIS AG / Key word (s): Conference SYGNIS presents your innovative True Prime (TM) technology on the Single Cell Genomics Conference 2015
09/10/2015 / 13:44
SYGNIS presenting your innovative True Prime (TM) technology on the Single Cell Genomics Conference 2015
Madrid, Spain and Heidelberg, August 10, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) announced today announced that it (TM) technology will be presenting at the Single Cell Genomics Conference in 2015, in front of experts from universities, companies, associations and government officials their proprietary True Prime. This year’s conference is organized by the Dutch Hubrecht Institute and take place from 16 to 18 September in Utrecht instead.
SYGNIS ‘True Prime (TM) product portfolio to amplify whole genomes from very small amounts of biological samples down to individual cells, based on a revolutionary new type of Multiple Displacement Amplifiations (MDA) technology for the multiplication of various DNA and RNA forms for various applications. Using the company’s proprietary DNA primase TthPrimPol the True Prime (TM) technology needs in contrast to the current standard technologies no synthetic “primer” (short DNA molecules, oligonucleotides) to start the reaction.
The properties of the True Prime (TM) technology make this product very attractive for a wide range of applications and analyzes, particularly in life science fields such as genomic analysis of single cells, where researchers need to gain biological information from the smallest sample quantities.
Armin Schneider, senior vice president of research at SYGNIS is a poster entitled True Prime (TM), a superior technology for single cell whole genome amplification based on TthPrimPol, imagine. The poster presentations will be held from 18:25 until 21:00 clock and on 17 September from 17:10 until 19:30 clock on 16 September.
The single-cell genomics is rapidly developing into an important technology for many areas of biological research. By the versatile application possibilities (sequencing of single-cell genomes, analyzing Einzelzelltranskriptomen, different approaches in the field of epigenetic profiling of single cells), researchers can characterize the genetic and functional properties of individual cells under native conditions, which opens up numerous experimental and clinical opportunities.
For more information on the Single Cell Genomics Conference 2015, please visit: http://www.weizmann.ac.il/conferences/SCG2015/welcome.
Über True Prime (TM)
True Prime (TM) is the brand name of a revolutionary, new Multiple Displacement Amplification and one of the key products in SYGNIS ‘portfolio. True Prime (TM) is based on the combination of the company’s DNA primase “TthPrimPol” with a highly processive and accurate Phi29 polymerase for uniform amplification of complete genomes for diverse applications such as Next Generation Sequencing (NGS) and the analysis of single cells. The extraordinary ability of Phi29 polymerase for the separation of DNA double strands allows the direct formation of new primer by TthPrimPol on the straight bared strands. These primers serve as attachment points for Phi29 polymerase, which then directly starts with the amplification, resulting in an exponential DNA amplification under isothermal conditions, without the use of previously necessary synthetic primers.
For more information please contact at:
SYGNIS AG MC Services AG Pilar de la Huerta Raimund Gabriel CEO / CFO Managing Partner Tel .: +34 91 192 36 50 Tel .: +49 89 210 228 30 Email: pdelahuerta @ sygnis.com Email: email@example.com
About SYGNIS AG: www.sygnis.com
SYGNIS, with headquarters in Germany and Spain, is specialized in the developing and commercializing innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio that addresses the key challenges in the rapidly growing fields of molecular biology and of Next Generation Sequencing. The main products of the company are on the one developed for the amplification and sequencing of complete genomes True Prime (TM) product line and SensiPhi (R), which has been licensed to an industry-leading partners. Furthermore, the product portfolio includes the SunScript (TM) reverse transcriptase product family for translating genetic information from RNA to DNA. SYGNIS AG is listed in the Prime Standard of the German Stock Exchange (ticker: LIO1; ISIN: DE000A1RFM03) listed
### Certain statements contained in this press release, which are not historical reported financial results nor other. These data, are forward-looking in nature. Such statements are mainly predictions of future events, trends, plans or objectives. Such statements are not be considered to be total guarantees since they are naturally subject to known and unknown risks and uncertainties and can be affected by other factors, differ in consequence of which the actual results and the plans and goals of SYGNIS materially from those expressed or implied by forward-looking statements can. SYGNIS does not undertake to update publicly or revise such statements, whether to reflect new information, future events or circumstances or otherwise. ###
09.10.2015 Dissemination of a Corporate News / Financial News, transmitted by DGAP – a service of EQS Group AG. For the content of this announcement The issuer / publisher is solely responsible.
DGAP’s Distribution Services include Regulatory Announcements, Financial / Corporate News and Press Releases. Media archive at and http://www.dgap-medientreff.de http://www.dgap.de
companies:. SYGNIS AG
Waldenhofer Str 104 69123 Heidelberg
Phone: 03222 1091 975
Fax: 03222 1096 030
exchanges: Regulated Market in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart
End of News DGAP News-Service
————– ————————————————– —–
393 705 09/10/2015